GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
GBA Initiates Coverage.>>>>>>>>Bridgeline Digital,
BLIN- With a four-week price change of 26.5%,
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. BLIN meets this criterion too, as the stock gained 14.7% over the past 12 weeks.
Moreover, the momentum for BLIN is fast paced, as the stock currently has a beta of 2.48. This indicates that the stock moves 148% higher than the market in either direction.
Given this price performance, it is no surprise that BLIN has a Momentum Score of B, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
Most importantly, despite possessing fast-paced momentum features, BLIN is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. BLIN is currently trading at 0.90 times its sales. In other words, investors need to pay only 90 cents for each dollar of sales.
So, BLIN appears to have plenty of room to run>>>>>>>>
Aug 11---
Bridgeline Digital, Inc. (BLIN) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 166.67%. A quarter ago, it was expected that this company would post a loss of $0.06 per share when it actually produced earnings of $0.03, delivering a surprise of 150%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Bridgeline Digital, Inc. (BLIN)
NasdaqCM - NasdaqCM Real Time Price.
1.3700-0.0300(-2.14%)
At close: September 6 04:02PM EDT
1.5200+0.1500(+10.9489%)<-------------------
Pre-Market:8:37AM EDT
BLIN- With a four-week price change of 26.5%,
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. BLIN meets this criterion too, as the stock gained 14.7% over the past 12 weeks.
Moreover, the momentum for BLIN is fast paced, as the stock currently has a beta of 2.48. This indicates that the stock moves 148% higher than the market in either direction.
Given this price performance, it is no surprise that BLIN has a Momentum Score of B, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
Most importantly, despite possessing fast-paced momentum features, BLIN is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. BLIN is currently trading at 0.90 times its sales. In other words, investors need to pay only 90 cents for each dollar of sales.
So, BLIN appears to have plenty of room to run>>>>>>>>
Aug 11---
Bridgeline Digital, Inc. (BLIN) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 166.67%. A quarter ago, it was expected that this company would post a loss of $0.06 per share when it actually produced earnings of $0.03, delivering a surprise of 150%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Bridgeline Digital, Inc. (BLIN)
NasdaqCM - NasdaqCM Real Time Price.
1.3700-0.0300(-2.14%)
At close: September 6 04:02PM EDT
1.5200+0.1500(+10.9489%)<-------------------
Pre-Market:8:37AM EDT
WATCH-DICE. Over 50 & 200 day----
DICE Therapeutics, Inc. (DICE)
NasdaqGM - NasdaqGM Real Time Price.
18.95+0.93(+5.16%)
At close: September 6 04:02PM EDT
19.17+0.22(+1.16%)
After hours:04:09PM EDT
DICE Therapeutics, Inc. (DICE)
NasdaqGM - NasdaqGM Real Time Price.
18.95+0.93(+5.16%)
At close: September 6 04:02PM EDT
19.17+0.22(+1.16%)
After hours:04:09PM EDT
<<<watch >>
-BLIN
-DICE
-BLIN
-DICE
Stoney, when it comes to stocks, I have a brain like fly-paper.
From May 5th:
It went from $31 to $24
Aug 17-- Stk was $1.40 where it closed yesterday>>>>>>>>>>
On that day...
Bridgeline Digital CEO buys $131K in common stock 08/18 BLIN n a regulatory filing, Bridgeline Digital disclosed that its CEO Roger Kahn bought 94.7K shares of common stock on August 17th in a total transaction size of $130.9K.
On that day...
Bridgeline Digital CEO buys $131K in common stock 08/18 BLIN n a regulatory filing, Bridgeline Digital disclosed that its CEO Roger Kahn bought 94.7K shares of common stock on August 17th in a total transaction size of $130.9K.
I'm liking these two.
Insider at DICE-
Over the last year, we can see that the biggest insider purchase was by Independent Director James Scopa for US$102k worth of shares, at about US$17.00 per share.
We noticed with Pfizer they made some great purchases recently... well maybe they paid too much but they swallowed up some good bios...(BHVN)
And I have no proof of this but I believe we are on the cusp of a big M&A spree in Bio.>>>
Will Novartis pick up the Dice?
The wildcard -, Dice Therapeutics (DICE ), focuses on blocking a molecule called IL-17. Inhibition of IL-17 suppresses an overactive immune system -- something that's important to do when combating a variety of autoimmune disorders, such as plaque psoriasis.
Currently, a number of monoclonal antibody therapies seek to suppress IL-17. Novartis, in fact, just posted $1.2 billion in sales in the first quarter for its own IL-17-inhibiting injectable treatment, Cosentyx.
Dice is developing a treatment too, but this would be an oral one, which patients might prefer. The potential is great given that the injectable IL-17 biologics market is projected to exceed $11 billion in sales by 2026. While Dice does not yet have clinical trial results, phase 1 data for its IL-17 blocking pill, DC-806, is expected in mid-2022.<-- Tic Tic Tic!
Historically, the IL-17 injectables have offered 77% to 90% efficacy for psoriasis. While we don't yet know what efficacy Dice's potential therapy might show, existing oral treatments, such as Amgen's Otezla, have managed to generate $1.8 billion in sales last year -- and that despite a 29% to 33% efficacy rate for psoriasis.<-- LOW BAR!!!!
With Cosentyx as its top-selling drug in the quarter, Novartis might be wise to protect its position in the IL-17 market with a potential oral treatment as well. And it could do so without breaking the bank by purchasing Dice, which currently has a market cap of around $750 million.
OOOoooooomph. DICE IS A BUY FOLKS.......
And I have no proof of this but I believe we are on the cusp of a big M&A spree in Bio.>>>
Will Novartis pick up the Dice?
The wildcard -, Dice Therapeutics (DICE ), focuses on blocking a molecule called IL-17. Inhibition of IL-17 suppresses an overactive immune system -- something that's important to do when combating a variety of autoimmune disorders, such as plaque psoriasis.
Currently, a number of monoclonal antibody therapies seek to suppress IL-17. Novartis, in fact, just posted $1.2 billion in sales in the first quarter for its own IL-17-inhibiting injectable treatment, Cosentyx.
Dice is developing a treatment too, but this would be an oral one, which patients might prefer. The potential is great given that the injectable IL-17 biologics market is projected to exceed $11 billion in sales by 2026. While Dice does not yet have clinical trial results, phase 1 data for its IL-17 blocking pill, DC-806, is expected in mid-2022.<-- Tic Tic Tic!
Historically, the IL-17 injectables have offered 77% to 90% efficacy for psoriasis. While we don't yet know what efficacy Dice's potential therapy might show, existing oral treatments, such as Amgen's Otezla, have managed to generate $1.8 billion in sales last year -- and that despite a 29% to 33% efficacy rate for psoriasis.<-- LOW BAR!!!!
With Cosentyx as its top-selling drug in the quarter, Novartis might be wise to protect its position in the IL-17 market with a potential oral treatment as well. And it could do so without breaking the bank by purchasing Dice, which currently has a market cap of around $750 million.
OOOoooooomph. DICE IS A BUY FOLKS.......